Arabic Arabic English English French French German German
dark

Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents

Remain vigilant for signs and symptoms of bleeding complications during treatment with DOACs (apixaban, dabigatran, edoxaban, rivaroxaban), especially in patients with increased bleeding risks.
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by HFACULTY News. Publisher: Search Click this link to read the full content from the Publisher Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Letters and drug alerts sent to healthcare professionals in May 2020

Next Post

Cyproterone acetate: new advice to minimise risk of meningioma

Related Posts
Total
0
Share